Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

01-09-2015 | Research Article

A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer

Authors: Lei Fan, Wulan Li, Shilong Ying, Lingyi Shi, Zhe Wang, Gaozhi Chen, Hui Ye, Xiaoping Wu, Jianzhang Wu, Guang Liang, Xiaokun Li

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Fibroblast growth factor 2 (FGF2) plays a critical role in tumorigenesis and progression of solid tumor and is upregulated in gastric carcinoma serum. Therefore, it is regarded as a potential therapeutic target of human gastric cancer. Suppression of bioactivities of FGF2 may contribute to human gastric cancer therapy. Herein, we obtained a novel FGF2-binding peptide derivative (named P32), which originated from a previously isolated P7 peptide with poor stability. We proved that P32, which had a half-life in human plasma up to 12 h, enhanced stability and exerted strong inhibitory effect on FGF2-induced cell proliferation and invasion in human gastric cancer cell lines. Further investigations revealed that the underlying anti-proliferation mechanisms of P32 in vitro included arresting FGF2-stimulated cells at the G0/G1 phase and reducing the activation of AKT and Erk1/2 cascades. The FGF2-binding peptide derivative P32 has improved stability, is relatively safe, and may have therapeutic potential in FGF2-driven gastric cancer.
Literature
1.
Matsumoto S, Tanaka R, Okada K, Arita K, Hyakusoku H, Miyamoto M, et al. The effect of control-released basic fibroblast growth factor in wound healing: histological analyses and clinical application. Plast Reconstr Surg Glob Open. 2013;1:e44.CrossRefPubMedPubMedCentral
2.
He B, Lin J, Li J, Mi Y, Zeng W, Zhang C. Basic fibroblast growth factor suppresses meiosis and promotes mitosis of ovarian germ cells in embryonic chickens. Gen Comp Endocrinol. 2012;176:173–81.CrossRefPubMed
3.
Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005;16:179–86.CrossRefPubMed
4.
Bieker R, Padro T, Kramer J, Steins M, Kessler T, Retzlaff S, et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res. 2003;63:7241–6.PubMed
5.
Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002;9:1–11.CrossRefPubMed
6.
Li Q, Gao S, Yu Y, Wang W, Chen X, Wang R, et al. A novel bFGF antagonist peptide inhibits breast cancer cell growth. Mol Med Rep. 2012;6:210–4.PubMed
7.
Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. 2012;84:149–60.CrossRefPubMed
8.
Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, et al. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer. 2003;106:34–44.CrossRefPubMed
9.
Bilgic I, Ozalp N, Tez M, Koc M. Serum bFGF concentrations in gastric cancer patients. Bratisl Lek Listy. 2008;109:8–9.PubMed
10.
11.
Zhu XB, Tang SB, Luo Y, Huang XK. The inhibiting effects of suramin on bFGF induced proliferation of cultured human RPE cells. Zhonghua Yan Ke Za Zhi. 2005;41:110–3.PubMed
12.
Sola F, Capolongo L, Moneta D, Ubezio P, Grandi M. The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156e, a growth-factor-complexing molecule. Cancer Chemother Pharmacol. 1999;43:241–6.CrossRefPubMed
13.
Furman JL, Chiu M, Hunter MJ. Early engineering approaches to improve peptide developability and manufacturability. AAPS J. 2015;17:111–20.CrossRefPubMed
14.
Wang C, Lin S, Nie Y, Jia X, Wang J, Xiao J, et al. Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Sci. 2010;101:1212–8.CrossRefPubMed
15.
Fan L, Xie H, Chen L, Ye H, Ying S, Wang C, et al. A novel FGF2 antagonist peptide P8 with potent antiproliferation activity. Tumour Biol. 2014;35:10571–9.CrossRefPubMed
16.
Facchiano A, Russo K, Facchiano AM, De Marchis F, Facchiano F, Ribatti D, et al. Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. J Biol Chem. 2003;278:8751–60.CrossRefPubMed
17.
Macindoe G, Mavridis L, Venkatraman V, Devignes MD, Ritchie DW. Hexserver. An FFT-based protein docking server powered by graphics processors. Nucleic Acids Res. 2010;38:5.CrossRef
18.
Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007;13:2025–44.CrossRefPubMed
19.
20.
Sipova H, Homola J. Surface plasmon resonance sensing of nucleic acids: a review. Anal Chim Acta. 2013;773:9–23.CrossRefPubMed
21.
Karlsson R. SPR for molecular interaction analysis: a review of emerging application areas. J Mol Recognit. 2004;17:151–61.CrossRefPubMed
22.
Campbell K, Huet AC, Charlier C, Higgins C, Delahaut P, Elliott CT. Comparison of elisa and SPR biosensor technology for the detection of paralytic shellfish poisoning toxins. J Chromatogr B Anal Technol Biomed Life Sci. 2009;877:4079–89.CrossRef
23.
Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell. 1999;98:641–50.CrossRefPubMed
24.
Yang ZL, Cheng K, Han ZD. Effect of bFGF on the MCF-7 cell cycle with CD44(+)/CD24(−): promoting the G0/G1→G2/S transition. J Breast Cancer. 2012;15:388–92.CrossRefPubMedPubMedCentral
25.
26.
Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/aAKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 2010;70:4151–62.CrossRefPubMed
27.
Liu ZC, Wang HS, Zhang G, Liu H, Chen XH, Zhang F, et al. AKT/GSK-3beta regulates stability and transcription of snail which is crucial for bFGF-induced epithelial-mesenchymal transition of prostate cancer cells. Biochim Biophys Acta. 1840;2014:3096–105.
28.
Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013;52:855–68.CrossRefPubMed
29.
Bruckdorfer T, Marder O, Albericio F. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr Pharm Biotechnol. 2004;5:29–43.CrossRefPubMed
30.
Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem. 2002;9:963–78.CrossRefPubMed
31.
Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides. 2001;22:2329–43.CrossRefPubMed
32.
Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013;447:75–93.CrossRefPubMedPubMedCentral
Metadata
Title
A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer
Authors
Lei Fan
Wulan Li
Shilong Ying
Lingyi Shi
Zhe Wang
Gaozhi Chen
Hui Ye
Xiaoping Wu
Jianzhang Wu
Guang Liang
Xiaokun Li
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3435-x

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Review

Breast cancer circulating biomarkers: advantages, drawbacks, and new insights

Research Article

Involvement of multiple cellular pathways in regulating resistance to tamoxifen in BIK-suppressed MCF-7 cells

Retraction Note

Retraction Note to: Correlations of IFN-γ genetic polymorphisms with susceptibility to breast cancer: a meta-analysis

Research Article

RETRACTED ARTICLE: Risperidone promotes differentiation of glioma stem-like cells through the Wnt signaling pathway

Research Article

MicroRNA signatures in total peripheral blood of gallbladder cancer patients

Research Article

Expression of myeloid zinc finger 1 and the correlation to clinical aspects of oral squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits